BioDelivery on track for mid-year NDA filing
BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product...
View ArticleBioDelivery posts disappointing Clonidine trial results
Shares of BioDelivery Sciences International (NASDAQ:BDSI) lost more than a quarter of their market value at the mid-session on Monday after the company announced disappointing Phase 3 trial results...
View Article
More Pages to Explore .....